Trial Profile
Efficacy and safety of bevacizumab, eribulin, and oxaliplatin in patients with platinum-resistant ovarian carcinomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Eribulin (Primary) ; Oxaliplatin (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology